Literature DB >> 8687474

Nitric oxide (NO), the only nitrogen monoxide redox form capable of activating soluble guanylyl cyclase.

E A Dierks1, J N Burstyn.   

Abstract

In the present study, we determined that of the redox forms of nitrogen monoxide, NO-, NO and NO+, only NO significantly activates soluble guanylyl cyclase (GTP pyrophosphate-lyase cyclizing, EC 4.6.1.2). Neither of the NO-donors tested, Angeli's salt (Na2N2O3) or Piloty's acid (C6H5SO2NHOH), caused a change in the guanylyl cyclase activity relative to the basal activity level. Interference by other reaction products was eliminated as a possible explanation for the lack of activation. To the extent that NO+ could be stabilized in aqueous solution, by dissolution of the nitrosonium salt NOPF6 in dry organic solvent prior to addition to the enzyme in buffer, NO+ had no effect on the activity of soluble guanylyl cyclase. The counter-ion, PF6-, had a minimal effect on the enzyme activity and, therefore was, not responsible for the lack of activation by NO+. These observations suggest that NO- is the natural activator of soluble guanylyl cyclase and is reasonably identical with endothelium-derived relaxing factor, the physiological regulator of soluble guanylyl cyclase activity.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8687474     DOI: 10.1016/0006-2952(96)00078-0

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  28 in total

1.  Comparison of the redox forms of nitrogen monoxide with the nitrergic transmitter in the rat anococcygeus muscle.

Authors:  C G Li; J Karagiannis; M J Rand
Journal:  Br J Pharmacol       Date:  1999-06       Impact factor: 8.739

2.  Nitric oxide is consumed, rather than conserved, by reaction with oxyhemoglobin under physiological conditions.

Authors:  Mahesh S Joshi; T Bruce Ferguson; Tae H Han; Daniel R Hyduke; James C Liao; Tienush Rassaf; Nathan Bryan; Martin Feelisch; Jack R Lancaster
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-17       Impact factor: 11.205

3.  A novel role for HNO in local and spreading vasodilatation in rat mesenteric resistance arteries.

Authors:  Kathryn H Yuill; Polina Yarova; Barbara K Kemp-Harper; Christopher J Garland; Kim A Dora
Journal:  Antioxid Redox Signal       Date:  2010-10-07       Impact factor: 8.401

Review 4.  The pharmacology of nitroxyl (HNO) and its therapeutic potential: not just the Janus face of NO.

Authors:  Nazareno Paolocci; Matthew I Jackson; Brenda E Lopez; Katrina Miranda; Carlo G Tocchetti; David A Wink; Adrian J Hobbs; Jon M Fukuto
Journal:  Pharmacol Ther       Date:  2006-11-29       Impact factor: 12.310

5.  Nitric oxide increases the enzymatic activity of three ascorbate peroxidase isoforms in soybean root nodules.

Authors:  Marshall Keyster; Ashwil Klein; Ifeanyi Egbichi; Alex Jacobs; Ndiko Ludidi
Journal:  Plant Signal Behav       Date:  2011-07

6.  The transcription regulator RcoM-2 from Burkholderia xenovorans is a cysteine-ligated hemoprotein that undergoes a redox-mediated ligand switch.

Authors:  Katherine A Marvin; Robert L Kerby; Hwan Youn; Gary P Roberts; Judith N Burstyn
Journal:  Biochemistry       Date:  2008-08-02       Impact factor: 3.162

7.  The shy Angeli and his elusive creature: the HNO route to vasodilation.

Authors:  Nazareno Paolocci; David A Wink
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-03-13       Impact factor: 4.733

8.  Protein disulfide-isomerase mediates delivery of nitric oxide redox derivatives into platelets.

Authors:  Susannah E Bell; Chirag M Shah; Michael P Gordge
Journal:  Biochem J       Date:  2007-04-15       Impact factor: 3.857

9.  Oxidation of nitroxyl anion to nitric oxide by copper ions.

Authors:  S Nelli; M Hillen; K Buyukafsar; W Martin
Journal:  Br J Pharmacol       Date:  2000-09       Impact factor: 8.739

Review 10.  Therapeutic Potential of Nitroxyl (HNO) Donors in the Management of Acute Decompensated Heart Failure.

Authors:  Barbara K Kemp-Harper; John D Horowitz; Rebecca H Ritchie
Journal:  Drugs       Date:  2016-09       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.